查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494793

到 2030 年甲狀腺癌診斷的全球市場預測：按產品、癌症類型、測試類型、癌症階段、診斷技術、最終用戶和地區進行分析

Thyroid Cancer Diagnostics Market Forecasts to 2030 - Global Analysis By Product (Assay Kits, Instruments, Reagents, Consumables and Other Products), Cancer Type, Test Type, Cancer Stage, Diagnostic Technique, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球甲狀腺癌診斷市場規模為 28.2 億美元，預計在預測期內將以 5.6% 的年複合成長率成長，到 2030 年達到 93.7 億美元。

甲狀腺癌診斷涉及一系列醫學評估和測試，以檢測和表徵甲狀腺癌。這些診斷工具可以幫助確定甲狀腺癌的存在、類型和階段，並指導適當的治療策略。早期發現可以及時介入並改善治療結果和存活率。準確的診斷有助於臨床醫生製定適當的治療計劃，最大限度地減少不必要的手術並降低醫療成本。

據美國癌症協會稱，2021 年可能會發現約 44,280 例新的甲狀腺癌病例。

越來越重視客製化治療

個人化醫療策略強調準確的診斷，以識別與癌症相關的特定基因突變和生物標記。這需要使用先進的診斷技術，例如分子測試和基因組分析。因此，醫療保健提供者越來越依賴全面的診斷方法來準確表徵甲狀腺癌亞型，並能夠根據患者的個別需求制定治療方法。這一趨勢透過促進先進診斷技術的採用，推動了甲狀腺癌診斷市場的擴張。

誤報和過度診斷

假陽性可能導致不必要的切片檢查、手術和治療，給患者帶來身體和情緒上的痛苦。過度診斷會導致進行性和非進行性癌症進行不必要的標記和治療，進一步導致醫療資源緊張。這削弱了人們對診斷測試和治療的信心，並阻止患者和醫療保健提供者使用它們，從而阻礙了該領域的市場擴張和創新。

加大醫療基礎建設投資

增加對醫療保健基礎設施的投資將改善獲得先進診斷技術和服務的機會。對現代醫療設施、設備和培訓的投資將使醫療保健提供者能夠更準確、更及時地診斷甲狀腺癌。改善基礎設施也有助於早期發現和治療，從長遠來看可以改善患者的治療效果並降低醫療成本。此外，醫療基礎設施的擴張將促進研究和開發，促進技術創新和新診斷方法的引入，進一步刺激市場成長。

昂貴的測試和技術

由於其複雜性和特異性，甲狀腺癌的診斷通常需要昂貴的測試和技術。先進的成像技術、分子測試和切片檢查程序導致了高昂的成本。這些費用可能會阻礙患者及時尋求診斷和治療，特別是在醫療保健資源有限或保險覆蓋範圍不足的地區。此外，高成本可能導致醫療保健預算緊張，限制診斷服務的獲取，並阻礙市場成長。

COVID-19 的影響

COVID-19 的爆發擾亂了醫療保健服務，包括例行檢查和擇期手術的延誤，從而影響了甲狀腺癌診斷市場。隨著患者前往醫療機構就診的次數減少，並且資源被用於對抗這場流行病，診斷檢測量也有所減少。然而，遠端醫療以及醫療保健業務的逐步恢復正常業務預計將支持疫情後的市場復甦。

預計臨床前診斷領域在預測期內將是最大的。

預計晚期診斷領域將出現良好的成長。晚期甲狀腺癌的診斷著重準確、全面的評估，以指導治療計畫。這使得醫療保健提供者能夠根據癌症的特異性特徵量身定做治療計劃，從而實現更個人化和標靶治療。整體而言，晚期甲狀腺癌的準確診斷有助於改善預後、生活品質和整體醫療資源利用率。

預計診斷影像在預測期內將表現出最高的年複合成長率

預計診斷成像在預測期內將經歷最高的年複合成長率。癌症診斷影像使用多種技術，包括 MRI、 電腦斷層掃描、PET 掃描、超音波和分子影像，以可視化腫瘤並評估其特徵、大小、位置和轉移潛力。這些非侵入性方法可以幫助早期發現癌症、分期、規劃治療並監測其進展。功能和分子成像等療法提供了對腫瘤生物學的深入了解，並指導個人化治療方法以改善患者的治療結果。

比最大的地區

由於甲狀腺癌發病率上升、醫療基礎設施改善以及早期檢測意識不斷增強，預計亞太地區將在預測期內佔據最大的市場佔有率。中國、印度和日本等國家人口眾多且醫療保健系統發達，導致診斷測試的需求激增。此外，診斷技術的進步和政府改善癌症護理的舉措正在進一步推動市場擴張。

年複合成長率最高的地區：

由於甲狀腺癌發病率增加、診斷技術的進步以及早期檢測意識的提高，預計北美在預測期內將呈現最高的年複合成長率。該市場受益於強大的醫療基礎設施和對研發的大量投資。此外，精準醫療和個人化醫療保健的日益普及也推動了該地區的市場擴張。美國和加拿大是這一市場成長的主要貢獻者。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球甲狀腺癌診斷市場：依產品

  • 檢測套件
  • 裝置
  • 試劑
  • 消耗品
  • 其他產品

第6章全球甲狀腺癌診斷市場：依癌症類型分類

  • 甲狀腺乳突癌
  • 濾泡性甲狀腺癌
  • 甲狀腺髓樣癌
  • 未分化甲狀腺癌
  • 其他癌症類型

第7章全球甲狀腺癌診斷市場：依測試類型

  • 診斷測試
  • 監控檢查

第8章全球甲狀腺癌診斷市場：依癌症階段分類

  • 早期診斷
  • 晚期診斷

第9章全球甲狀腺癌診斷市場：依診斷技術分類

  • 影像
  • 驗血
  • 分子診斷
  • 切片檢查
  • 其他診斷技術

第10章全球甲狀腺癌診斷市場：依最終用戶分類

  • 診斷實驗室
  • 學術研究所
  • 專科診所
  • 醫院

第11章全球甲狀腺癌診斷市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Abbott Laboratories
  • Roche Limited
  • Thermo Fisher Scientific
  • Siemens Healthcare
  • Bio-Rad Laboratories
  • General Electric
  • Koninklijke Philips NV
  • Toshiba Corporation
  • Agilent Technologies
  • Illumina Inc.
  • BioMerieux SA
  • Biocare Medical LLC
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • PerkinElmer Inc.
  • Quest Diagnostics Incorporated
  • Bayer AG
Product Code: SMRC26308

According to Stratistics MRC, the Global Thyroid Cancer Diagnostics Market is accounted for $2.82 billion in 2024 and is expected to reach $9.37 billion by 2030 growing at a CAGR of 5.6% during the forecast period. Thyroid cancer diagnostics involve a series of medical evaluations and tests to detect and characterize thyroid cancer. These diagnostic tools help determine the presence, type, and stage of thyroid cancer, guiding appropriate treatment strategies. Early detection enables timely intervention, improving treatment outcomes and survival rates. Accurate diagnosis helps clinicians tailor appropriate treatment plans, minimizing unnecessary procedures and reducing healthcare costs.

According to the American Cancer Society, about 44,280 new thyroid cancer patients may be detected in 2021.

Market Dynamics:

Driver:

Growing focus on tailored treatment plans

Personalized medicine strategies emphasize the importance of precise diagnosis to identify specific genetic mutations or biomarkers associated with the cancer. This necessitates the use of sophisticated diagnostic techniques such as molecular testing and genomic analysis. Consequently, healthcare providers increasingly rely on comprehensive diagnostic approaches to accurately characterize thyroid cancer subtypes, enabling them to tailor treatment regimens according to individual patient needs. This trend fuels the expansion of the thyroid cancer diagnostics market by driving adoption of advanced diagnostic technologies.

Restraint:

False positives and over diagnosis

False positives can lead to unnecessary biopsies, surgeries, and treatments, causing physical and psychological distress to patients. Over diagnosis can result in the unnecessary labeling and treatment of indolent or non-progressive cancers, further burdening healthcare resources. This undermines confidence in diagnostic tests and treatments, discouraging both patients and healthcare providers from utilizing them, thereby impeding market expansion and innovation in the field.

Opportunity:

Increased investments in healthcare infrastructure

Increased investments in healthcare infrastructure enhance access to advanced diagnostic technologies and services. Investments in modern medical facilities, equipment, and training enable healthcare providers to offer more accurate and timely diagnosis of thyroid cancer. Improved infrastructure also facilitates early detection and treatment, leading to better patient outcomes and reduced healthcare costs in the long term. Moreover, expanded healthcare infrastructure fosters research and development, driving innovation and the introduction of new diagnostic methods, further stimulating market growth.

Threat:

Expensive tests and technologies

Thyroid cancer diagnostics often involve expensive tests and technologies due to their complexity and specialized nature. Advanced imaging techniques, molecular testing, and biopsy procedures contribute to high costs. These expenses can deter patients from seeking timely diagnosis and treatment, particularly in regions with limited healthcare resources or inadequate insurance coverage. Moreover, high costs may strain healthcare budgets, limiting access to diagnostic services and impeding market growth.

Covid-19 Impact

The covid-19 pandemic has influenced the thyroid cancer diagnostics market by causing disruptions in healthcare services, including delays in routine screenings and elective procedures. Reduced patient visits to healthcare facilities and reallocation of resources towards managing the pandemic have led to a decline in diagnostic testing volumes. However, increased emphasis on telemedicine and the gradual return to normal healthcare operations are expected to support market recovery post-pandemic.

The advanced-stage diagnosis segment is expected to be the largest during the forecast period

The advanced-stage diagnosis segment is estimated to have a lucrative growth. Advanced-stage thyroid cancer diagnosis focuses on precise and comprehensive evaluation to guide treatment plans. It enables healthcare providers to tailor treatment plans according to the specific characteristics of the cancer, leading to more personalized and targeted therapies. Overall, accurate thyroid cancer diagnostics in advanced stages contribute to better prognosis, quality of life, and overall healthcare resource utilization.

The imaging segment is expected to have the highest CAGR during the forecast period

The imaging segment is anticipated to witness the highest CAGR growth during the forecast period. Imaging cancer diagnostics employ various techniques such as MRI, CT scans, PET scans, ultrasound, and molecular imaging to visualize tumours and assess their characteristics, size, location, and potential metastasis. These non-invasive methods aid in early detection, staging, treatment planning, and monitoring of cancer progression. Advancements like functional and molecular imaging provide insights into tumor biology, guiding personalized treatment approaches for improved patient outcomes.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period due to rising incidences of thyroid cancer, improving healthcare infrastructure, and increasing awareness about early detection. Countries like China, India, and Japan are witnessing a surge in demand for diagnostic tests driven by their large population bases and evolving healthcare systems. Moreover, advancements in diagnostic technologies and government initiatives to improve cancer care further fuel market expansion.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, driven by increasing thyroid cancer incidence, advancements in diagnostic technologies, and rising awareness about early detection. The market benefits from strong healthcare infrastructure and significant investments in research and development. Additionally, the growing adoption of precision medicine and personalized healthcare approaches further propels market expansion in this region. The United States and Canada are the primary contributors to this market growth.

Key players in the market

Some of the key players profiled in the Thyroid Cancer Diagnostics Market include Abbott Laboratories, Roche Limited, Thermo Fisher Scientific, Siemens Healthcare, Bio-Rad Laboratories, General Electric, Koninklijke Philips N.V., Toshiba Corporation, Agilent Technologies, Illumina Inc., BioMerieux SA, Biocare Medical LLC, Danaher Corporation, F. Hoffmann-La Roche AG, PerkinElmer Inc., Quest Diagnostics Incorporated and Bayer AG.

Key Developments:

In April 2024, Bio-Rad Laboratories, Inc. launched the ddPLEX ESR1 Mutation Detection Kit, its first ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection in clinical research. The assay is designed for Bio-Rad's QX600(TM) Droplet Digital(TM) PCR and can detect, discriminate, and quantify key mutations in the ESR1 gene for breast cancer.

In March 2024, Bayer AG and Thermo Fisher Scientific Inc. announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These will help identify patients who may benefit from Bayer's growing portfolio of precision cancer therapies by offering decentralized genomic testing and rapid turnaround time.

Products Covered:

  • Assay Kits
  • Instruments
  • Reagents
  • Consumables
  • Other Products

Cancer Types Covered:

  • Papillary Thyroid Cancer
  • Follicular Thyroid Cancer
  • Medullary Thyroid Cancer
  • Anaplastic Thyroid Cancer
  • Other Cancer Types

Test Types Covered:

  • Diagnostic Tests
  • Monitoring Tests

Cancer Stages Covered:

  • Early-Stage Diagnosis
  • Advanced-Stage Diagnosis

Diagnostic Techniques Covered:

  • Imaging
  • Blood Tests
  • Molecular Diagnostics
  • Biopsy
  • Other Diagnostic Techniques

End Users Covered:

  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Specialty Clinics
  • Hospitals

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Thyroid Cancer Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Assay Kits
  • 5.3 Instruments
  • 5.4 Reagents
  • 5.5 Consumables
  • 5.6 Other Products

6 Global Thyroid Cancer Diagnostics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Papillary Thyroid Cancer
  • 6.3 Follicular Thyroid Cancer
  • 6.4 Medullary Thyroid Cancer
  • 6.5 Anaplastic Thyroid Cancer
  • 6.6 Other Cancer Types

7 Global Thyroid Cancer Diagnostics Market, By Test Type

  • 7.1 Introduction
  • 7.2 Diagnostic Tests
  • 7.3 Monitoring Tests

8 Global Thyroid Cancer Diagnostics Market, By Cancer Stage

  • 8.1 Introduction
  • 8.2 Early-Stage Diagnosis
  • 8.3 Advanced-Stage Diagnosis

9 Global Thyroid Cancer Diagnostics Market, By Diagnostic Technique

  • 9.1 Introduction
  • 9.2 Imaging
  • 9.3 Blood Tests
  • 9.4 Molecular Diagnostics
  • 9.5 Biopsy
  • 9.6 Other Diagnostic Techniques

10 Global Thyroid Cancer Diagnostics Market, By End User

  • 10.1 Introduction
  • 10.2 Diagnostic Laboratories
  • 10.3 Academic & Research Institutes
  • 10.4 Specialty Clinics
  • 10.5 Hospitals

11 Global Thyroid Cancer Diagnostics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott Laboratories
  • 13.2 Roche Limited
  • 13.3 Thermo Fisher Scientific
  • 13.4 Siemens Healthcare
  • 13.5 Bio-Rad Laboratories
  • 13.6 General Electric
  • 13.7 Koninklijke Philips N.V.
  • 13.8 Toshiba Corporation
  • 13.9 Agilent Technologies
  • 13.10 Illumina Inc.
  • 13.11 BioMerieux SA
  • 13.12 Biocare Medical LLC
  • 13.13 Danaher Corporation
  • 13.14 F. Hoffmann-La Roche AG
  • 13.15 PerkinElmer Inc.
  • 13.16 Quest Diagnostics Incorporated
  • 13.17 Bayer AG

List of Tables

  • Table 1 Global Thyroid Cancer Diagnostics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Thyroid Cancer Diagnostics Market Outlook, By Product (2022-2030) ($MN)
  • Table 3 Global Thyroid Cancer Diagnostics Market Outlook, By Assay Kits (2022-2030) ($MN)
  • Table 4 Global Thyroid Cancer Diagnostics Market Outlook, By Instruments (2022-2030) ($MN)
  • Table 5 Global Thyroid Cancer Diagnostics Market Outlook, By Reagents (2022-2030) ($MN)
  • Table 6 Global Thyroid Cancer Diagnostics Market Outlook, By Consumables (2022-2030) ($MN)
  • Table 7 Global Thyroid Cancer Diagnostics Market Outlook, By Other Products (2022-2030) ($MN)
  • Table 8 Global Thyroid Cancer Diagnostics Market Outlook, By Cancer Type (2022-2030) ($MN)
  • Table 9 Global Thyroid Cancer Diagnostics Market Outlook, By Papillary Thyroid Cancer (2022-2030) ($MN)
  • Table 10 Global Thyroid Cancer Diagnostics Market Outlook, By Follicular Thyroid Cancer (2022-2030) ($MN)
  • Table 11 Global Thyroid Cancer Diagnostics Market Outlook, By Medullary Thyroid Cancer (2022-2030) ($MN)
  • Table 12 Global Thyroid Cancer Diagnostics Market Outlook, By Anaplastic Thyroid Cancer (2022-2030) ($MN)
  • Table 13 Global Thyroid Cancer Diagnostics Market Outlook, By Other Cancer Types (2022-2030) ($MN)
  • Table 14 Global Thyroid Cancer Diagnostics Market Outlook, By Test Type (2022-2030) ($MN)
  • Table 15 Global Thyroid Cancer Diagnostics Market Outlook, By Diagnostic Tests (2022-2030) ($MN)
  • Table 16 Global Thyroid Cancer Diagnostics Market Outlook, By Monitoring Tests (2022-2030) ($MN)
  • Table 17 Global Thyroid Cancer Diagnostics Market Outlook, By Cancer Stage (2022-2030) ($MN)
  • Table 18 Global Thyroid Cancer Diagnostics Market Outlook, By Early-Stage Diagnosis (2022-2030) ($MN)
  • Table 19 Global Thyroid Cancer Diagnostics Market Outlook, By Advanced-Stage Diagnosis (2022-2030) ($MN)
  • Table 20 Global Thyroid Cancer Diagnostics Market Outlook, By Diagnostic Technique (2022-2030) ($MN)
  • Table 21 Global Thyroid Cancer Diagnostics Market Outlook, By Imaging (2022-2030) ($MN)
  • Table 22 Global Thyroid Cancer Diagnostics Market Outlook, By Blood Tests (2022-2030) ($MN)
  • Table 23 Global Thyroid Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2022-2030) ($MN)
  • Table 24 Global Thyroid Cancer Diagnostics Market Outlook, By Biopsy (2022-2030) ($MN)
  • Table 25 Global Thyroid Cancer Diagnostics Market Outlook, By Other Diagnostic Techniques (2022-2030) ($MN)
  • Table 26 Global Thyroid Cancer Diagnostics Market Outlook, By End User (2022-2030) ($MN)
  • Table 27 Global Thyroid Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 28 Global Thyroid Cancer Diagnostics Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 29 Global Thyroid Cancer Diagnostics Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 30 Global Thyroid Cancer Diagnostics Market Outlook, By Hospitals (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.